Laboratory Co. of America (LH) to Release Earnings on Thursday

Laboratory Co. of America (NYSE:LH) will post its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect Laboratory Co. of America to post earnings of $3.78 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Laboratory Co. of America Stock Performance

NYSE:LH opened at $213.06 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88. Laboratory Co. of America has a fifty-two week low of $191.97 and a fifty-two week high of $234.09. The company has a market cap of $17.96 billion, a price-to-earnings ratio of 42.87, a PEG ratio of 1.59 and a beta of 1.05. The stock has a fifty day moving average price of $203.49 and a 200-day moving average price of $210.25.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Thursday, August 29th will be given a dividend of $0.72 per share. The ex-dividend date is Thursday, August 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.35%. Laboratory Co. of America’s dividend payout ratio is currently 57.95%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LH shares. Robert W. Baird upped their price objective on Laboratory Co. of America from $258.00 to $261.00 and gave the stock an “outperform” rating in a research report on Monday, July 8th. Barclays lowered their target price on Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. JPMorgan Chase & Co. lowered their target price on Laboratory Co. of America from $261.00 to $243.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. StockNews.com cut Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Tuesday, June 4th. Finally, Truist Financial lowered their target price on Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, April 26th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Laboratory Co. of America has an average rating of “Moderate Buy” and an average target price of $241.29.

Insider Buying and Selling

In related news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $210.83, for a total transaction of $421,660.00. Following the completion of the sale, the executive vice president now owns 5,637 shares of the company’s stock, valued at $1,188,448.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Kerrii B. Anderson sold 250 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $200.10, for a total transaction of $50,025.00. Following the completion of the sale, the director now owns 15,722 shares of the company’s stock, valued at $3,145,972.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Der Vaart Sandra D. Van sold 2,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $210.83, for a total value of $421,660.00. Following the completion of the transaction, the executive vice president now owns 5,637 shares in the company, valued at approximately $1,188,448.71. The disclosure for this sale can be found here. 0.85% of the stock is currently owned by insiders.

Laboratory Co. of America Company Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).